Nasdaq

Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19

TARRYTOWN, N.Y., July 20, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron's ...
The Inlander

It's no vaccine, but monoclonal antibody treatments can prevent severe COVID-19. Why is it so hard to find in the Inland Northwest?

Last year, former president Donald Trump called monoclonal antibodies a "cure" for COVID-19 and vowed to make them available for all Americans. After all, they were part of Trump's own treatment that ...
The New England Journal of Medicine

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

This phase 3, placebo-controlled platform trial evaluated a single infusion of casirivimab and imdevimab (REGEN-COV) at 2400-mg and 1200-mg doses in outpatients with acute SARS-CoV-2 infection. The ...
Morningstar

Maintaining Our $570 Regeneron Fair Value Estimate; Expect Eylea and Regen-Cov Pressure in 2022

We're maintaining our $570 fair value estimate for Regeneron after the firm reported strong third-quarter results, driven by what we see as a combination of near-term demand for COVID-19 antibody ...